Provided by Tiger Fintech (Singapore) Pte. Ltd.

ZHAOKE OPHTH-B

1.500
+0.000
Volume:549.50K
Turnover:818.67K
Market Cap:819.00M
PE:-3.24
High:1.520
Open:1.510
Low:1.470
Close:1.500
Loading ...

Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial

MT Newswires Live
·
Yesterday

Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal

MT Newswires Live
·
16 Apr

BRIEF-Zhaoke Ophthalmology Enters 3 Distribution Agreements With Interpharma

Reuters
·
16 Apr

Zhaoke Ophthalmology - Enters 3 Distribution Agreements With Interpharma to Commercialize Nvk002, Brimocho Tm Pf & 6 Glaucoma Drugs in Thailand

THOMSON REUTERS
·
16 Apr

Zhaoke Ophthalmology Shrinks Loss in 2024

MT Newswires Live
·
25 Mar

Stock Track | Zhaoke Ophthalmology Plummets 6.51% Following Annual Loss of RMB237.5 Million

Stock Track
·
25 Mar

BRIEF-Zhaoke Ophthalmology Posts Loss For Year RMB237.5 Mln

Reuters
·
24 Mar

Retail investors in Zhaoke Ophthalmology Limited (HKG:6622) are its biggest bettors, and their bets paid off as stock gained 22% last week

Simply Wall St.
·
13 Feb

Zhaoke Ophthalmology Procures Distributor for Presbyopia Drug in Australia, New Zealand

MT Newswires Live
·
13 Jan

BRIEF-Zhaoke Ophthalmology Announces Distribution Agreement With AFT Pharmaceuticals

Reuters
·
13 Jan

Zhaoke Ophthalmology Ltd - Entering Into Distribution- Agreement With AFT Pharmaceuticals

THOMSON REUTERS
·
13 Jan

Zhaoke Ophthalmology's Abbreviated NDA for Myopia Drug Accepted by Chinese Regulator

MT Newswires Live
·
03 Jan

BRIEF-Zhaoke Ophthalmology Says NMPA Acceptance Of New Drug Application For NVK002

Reuters
·
02 Jan

Zhaoke Ophthalmology - Nmpa Acceptance of Abbreviated New Drug- Application for Nvk002 for Treatment of- Myopia Progression in Children

THOMSON REUTERS
·
02 Jan

Zhaoke Ophthalmology's Phase 3 Trial for Macular Degeneration Drug Meets Endpoints; Shares Rise 7%

MT Newswires Live
·
02 Jan

Zhaoke Ophthalmology's Phase 3 Trial of Myopia Progression Drug Shows Positive Results

MT Newswires Live
·
23 Oct 2024